![ESMOGI24_Delegates_Venue_01](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-gi-2024/coverage/esmogi24_delegates_venue_01/19232663-1-eng-GB/esmogi24_delegates_venue_01_i770.jpg)
No significant survival benefits reported for perioperative chemoimmunotherapy in resectable G/GEJ cancers
Final results of the KEYNOTE-585 study indicate that the current treatment standard for resectable G/GEJ should remain unchanged
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.